Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Piotr Jan Błoński
Observed names:
Błoński, Piotr,
P. Blonski,
P. Błoński,
Piotr Blonski,
Piotr Błoński,
Piotr J. Błoński,
Piotr Jan Blonski,
Piotr, Blonski
show all 8
Institutions:
Medical University of Warsaw,
Medical University of Lodz,
The Maria Sklodowska-Curie National Research Institute of Oncology
Observed institutions:
Medical University of Warsaw,
Medical University of Lodz,
The Maria Sklodowska-Curie National Research Institute of Oncology
ORCID:
0009-0003-4289-7741
Observed ORCID:
0009-0003-4289-7741
OpenAlex ID:
A5093098850
Exploring the impact of NGS on diagnostics and treatment of sarcoma: insights from real-world data across multiple institutions in Europe
2025
·
A. Kyriazoglou
, A. Zając
, et al.
·
ESMO Open
·
7
Long‐term efficacy of neoadjuvant–adjuvant targeted therapy in borderline resectable stage IIIB–D and IV melanoma
2024
·
Anna M. Czarnecka
, Krzysztof Ostaszewski
, et al.
·
Cancer
·
5
PDF
Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma
2024
·
Piotr J. Błoński
, Anna M. Czarnecka
, et al.
·
Biomedicines
·
5
PDF
Preoperative-postoperative immunotherapy as treatment of borderline resectable and oligoprogressive stage III B-D and IV melanoma
2024
·
Anna M. Czarnecka
, Krzysztof Ostaszewski
, et al.
·
European Journal of Surgical Oncology
·
3
Establishing biomarkers for soft tissue sarcomas
2024
·
Anna M. Czarnecka
, Paulina Chmiel
, et al.
·
Expert Review of Anticancer Therapy
·
3
Discontinuation of Immune Checkpoint Inhibition in Patients with Advanced Unresectable Melanoma Achieving CR, PR, or SD
2025
·
Anna M. Czarnecka
, Paweł Teterycz
, et al.
·
Targeted Oncology
·
2
PDF
Real-world outcomes of metastatic clear cell sarcoma sequential chemotherapy
2024
·
Anna M. Czarnecka
, Paulina Chmiel
, et al.
·
Journal of Chemotherapy
·
2
Novel biomarkers in bone sarcomas — diagnosis, treatment selection, and clinical trials
2024
·
Anna M. Czarnecka
, Piotr Błoński
, et al.
·
Oncology in Clinical Practice
·
2
PDF
1115P Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice
2023
·
K. Piejko
, B. Cybulska-Stopa
, et al.
·
Annals of Oncology
·
2
PDF
Efficacy of perioperative chemotherapy and radiotherapy in patients diagnosed with mesenchymal and dedifferentiated chondrosarcoma
2025
·
A.M. Czarnecka
, P. Remiszewski
, et al.
·
European Journal of Surgical Oncology
·
1
Encorafenib with binimetinib efficacy in the first, second, and third line of treatment for patients with advanced melanoma harboring a BRAF mutation — real-world study
2025
·
Anna M. Czarnecka
, Piotr Błoński
, et al.
·
Oncology in Clinical Practice
·
1
PDF
1682P Outcomes of first-, second- and third-line treatment with all available combinations of BRAF plus MEK inhibitors in advanced melanoma patients: A real-world study
2025
·
A.M. Czarnecka
, P. Blonski
, et al.
·
Annals of Oncology
·
1
Long-term outcomes of sequential chemotherapy in epithelioid sarcoma
2024
·
Anna M. Czarnecka
, Paulina Chmiel
, et al.
·
Journal of Chemotherapy
·
1
Distal and proximal epithelioid sarcoma — differences in diagnosis and similarities in treatment
2024
·
Maria Krotewicz
, Anna M. Czarnecka
, et al.
·
Oncology in Clinical Practice
·
1
PDF
1176P Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study
2023
·
A.M. Czarnecka
, P. Teterycz
, et al.
·
Annals of Oncology
·
1
PDF
The value of ultrasound-guided core-needle biopsy in the diagnosis of retroperitoneal sarcomas
2026
·
Jacek Skoczylas
, Grzegorz Rosiak
, et al.
·
Polish Journal of Surgery
Radical treatment of extraskeletal myxoid chondrosarcoma: A retrospective analysis of long-term outcomes and inflammatory prognostic factors.
2026
·
Anna Malgorzata Czarnecka
, Piotr Remiszewski
, et al.
·
Journal of Clinical Oncology
PDF
Comparison of real-world effectiveness of all approved BRAF/MEK inhibitor combinations in BRAF -mutant melanoma patients.
2026
·
Anna Malgorzata Czarnecka
, Piotr Jan Blonski
, et al.
·
Journal of Clinical Oncology
PDF
Molecular biomarkers impact survival after neoadjuvant chemoradiation in locally advanced soft tissue sarcoma patients
2026
·
Klaudia Bobak
, Jakub Piątkowski
, et al.
·
Research Square
PDF
Long-term efficacy of radical treatment of patients with clear cell sarcoma
2026
·
Anna M. Czarnecka
, Piotr Błoński
, et al.
·
European Journal of Surgical Oncology
Outcomes of systemic treatment in advanced melanoma after progression on anti–PD-1 therapy: a real-world study with literature review
2026
·
Piotr J. Błoński
, Krzysztof Ostaszewski
, et al.
·
DOAJ (DOAJ: Directory of Open Access Journals)
268MO Analysis of rare clinical scenario in advanced/metastatic basal cell carcinoma (BCC) patients of cemiplimab therapy after progression on vismodegib
2026
·
M.E. Dudzisz-Sledz
, P. Blonski
, et al.
·
ESMO rare cancers.
141P Inflammatory prognostic factors and long-term outcomes of chondrosarcoma patients treated with palliative chemotherapy
2026
·
A.M. Czarnecka
, P. Remiszewski
, et al.
·
ESMO rare cancers.
PDF
Nectins and Nectin-like molecules in cancer: expression, function, and therapeutic implications in melanoma, lung cancer, and renal cell carcinoma
2026
·
Anna M. Czarnecka
, Michał Nizio
, et al.
·
Oncology in Clinical Practice
PDF
Surgical treatment of retroperitoneal sarcomas: analysis of multi-organ resections and factors influencing perioperative outcomes
2026
·
Jacek Skoczylas
, Iwona Kalinowska
, et al.
·
Współczesna Onkologia
Show more works
View as search
Works count:
41
Citation count:
38
H-index:
3
I10-index:
Year
Topic
Type